Extract from the above information

Cefotaxime is a third-generation cephalosporin with a broad antibacterial spectrum. It has strong activity against Gram-negative bacteria such as Escherichia coli, Proteus mirabilis, Klebsiella and Salmonella, and other Enterobacteriaceae. It also has a good effect on Proteus vulgaris and Citrobacter. Enterobacter cloacae and Enterobacter aerogenes are relatively resistant to this product. This product has no antibacterial activity against Pseudomonas aeruginosa and Alcaligenes. Cefotaxime has a strong effect on influenza bacilli, Neisseria gonorrhoeae (including β-lactamase-producing strains), Neisseria meningitidis and Moraxella catarrhalis. This product has poor antibacterial activity against Staphylococcus aureus, strong activity against Gram-positive cocci such as hemolytic Streptococcus and Streptococcus pneumoniae, and Enterococcus is resistant to this product.

It kills bacteria by inhibiting bacterial cell wall synthesis and has high resistance to β-lactamase produced by bacteria. Some common Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. It is resistant to Pseudomonas aeruginosa, most strains of enterococci, and Escherichia coli.

Etoposide is an effective component of lignans isolated from podophyllin. VP-16 is a cell cycle-specific anti-tumor drug that acts in the late S phase or G2 phase. Its action site is topoisomerase II, forming a stable cleavable complex between drug, enzyme and DNA, interfering with DNA topoisomerase II, making the damaged DNA unable to be repaired. By stabilizing the DNA breakage complex, it causes double-line breaks in DNA and topoisomerase II. It activates certain endonucleases in vivo, or acts on DNA through its metabolites, and its non-glycoside homologue 4-demethylepipodophyllotoxin can inhibit microtubule assembly.